Sugi Predict

Sugi Predict / Compounds / SCHEMBL1979734

SCHEMBL1979734

SCHEMBL1979734

CC(C)c1cccc(Oc2ccc(N)cn2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.67
▸ MEN1 O00255 4/20 0.67
▸ KMT2A Q03164 4/20 0.67
▸ ALDH1A1 P00352 4/20 0.67
▸ BRCA1 P38398 1/20 0.67
▸ HBB P68871 1/20 0.67
▸ HSD17B10 Q99714 1/20 0.67
▸ POLB P06746 3/20 0.52
▸ RAB9A P51151 1/20 0.49
▸ KEAP1 Q14145 1/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ MITF O75030 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ GFER P55789 1/20 0.42
▸ NLRP1 Q9C000 1/20 0.42
▸ NOD2 Q9HC29 1/20 0.42
▸ TSHR P16473 1/20 0.40
▸ ACACB O00763 1/20 0.40
▸ ACACA Q13085 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13160074 0.86 KDM4E (0.48) KDM4EMEN1KMT2AALDH1A1BRCA1
SCHEMBL1980037 0.82 KDM4E (0.71) KDM4EMEN1KMT2AALDH1A1BRCA1
SCHEMBL1979566 0.82 MEN1 (0.43) KDM4EMEN1KMT2AALDH1A1BRCA1
SCHEMBL15055942 0.81 KDM4E (0.63) KDM4EMEN1KMT2AALDH1A1BRCA1
SCHEMBL20931739 0.81 KDM4E (0.73) KDM4EMEN1KMT2AALDH1A1BRCA1
SCHEMBL23914560 0.79 MAPK1 (0.66) KMT2AALDH1A1POLBRAB9ASMN1; SMN2
SCHEMBL16659211 0.77 ALDH1A1 (0.40) KDM4EMEN1KMT2AALDH1A1BRCA1
SCHEMBL14782127 0.77 KDM4E (0.68) KDM4EMEN1KMT2AALDH1A1BRCA1
SCHEMBL6506490 0.77 KDM4E (0.68) KDM4EMEN1KMT2AALDH1A1BRCA1
SCHEMBL19317584 0.77 TLR4 (0.47) KDM4EMEN1KMT2ARAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11180461-B2 Triazoles as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-11-23 — — US disclosed
EP-2852589-B1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2021-04-28 — — EP disclosed
US-20200172496-A1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY SRL (IT) 2020-06-04 — — US disclosed
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 — — US disclosed
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 — — US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 — — US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 — — US disclosed
US-10611735-B2 Triazoles as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-07 — — US disclosed
US-20190071405-A1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2019-03-07 — — US disclosed
US-10160730-B2 Triazoles as KV3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2018-12-25 — — US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 — — US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 — — US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 — — US disclosed
WO-2013175215-A1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LIMITED (GB) 2013-11-28 — — WO disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 — — EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10611735-B2 Triazoles as Kv3 inhibitors KCNA3, KCNN3, KCNK3 KDM4E 1261/4885MEN1 2340/4885KMT2A 984/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 KDM4E 268/4885MEN1 1190/4885KMT2A 530/4885
US-20190071405-A1 TRIAZOLES AS KV3 INHIBITORS KCNA3, KCNN3, KCNK3 KDM4E 1261/4885MEN1 2340/4885KMT2A 984/4885
US-20200172496-A1 TRIAZOLES AS KV3 INHIBITORS KCNA3, KCNN3, KCNK3 KDM4E 1261/4885MEN1 2340/4885KMT2A 984/4885
US-11180461-B2 Triazoles as Kv3 inhibitors KCNA3, KCNN3, KCNK3 KDM4E 1261/4885MEN1 2340/4885KMT2A 984/4885
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KDM4E 268/4885MEN1 1190/4885KMT2A 530/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 KDM4E 280/4885MEN1 1645/4885KMT2A 586/4885
US-10160730-B2 Triazoles as KV3 inhibitors KCNA3, KCNN3, KCNK3 KDM4E 1261/4885MEN1 2340/4885KMT2A 984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.